Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Hydroxychloroquine · 1 trial · 2 indications
Recurrence will be defined as the development of grade ≥2 irAA in a participant whose symptoms initially improved to grade ≤1. Symptoms will be investigator assessed and graded according to CTCAEv5.0.
| Arm | Type | Description |
|---|---|---|
| Hydroxychloroquine, plus prednisone | EXPERIMENTAL | Hydroxychloroquine 5mg/kg PO daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose. |
| Hydroxychloroquine-matching placebo, plus prednisone | PLACEBO_COMPARATOR | Matching placebo daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose. |
| Name | Type | Description |
|---|---|---|
| Hydroxychloroquine | DRUG | Hydroxychloroquine 5mg/kg PO daily |
| Placebo | OTHER | Hydroxychloroquine-matching placebo |
Inclusion Criteria: 1. Patients must be 18 years of age, or older; 2. Patients must be capable of providing consent to enrolment and treatment. 3. Patients with a performance status of ECOG 0-2 will be eligible for enrolment (see appendix A). 4. Patients with histologically confirmed cancer receivi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 5 | PHASE4 | Undisclosed |
| Smith & Nephew plc Sponsored ADR | SNN | 3 | PHASE4 | Undisclosed |
| Johnson & Johnson | JNJ | 1 | PHASE4 | Undisclosed |
Hydroxychloroquine is being studied for use in arthritis and arthralgia. It is an investigational small molecule in Phase 2 clinical development for these conditions. The drug is being evaluated in a randomized, double-blind, placebo-controlled trial to assess its effects on immune-mediated pathophysiology related to joint symptoms.
Hydroxychloroquine is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company is conducting a Phase 2 clinical trial of the drug for arthritis and arthralgia. Avalon GloboCare Corp. trades under the ticker symbol ALBT.
Hydroxychloroquine is in Phase 2 clinical development for arthritis and arthralgia. It is an investigational drug, meaning it has not been approved by regulatory authorities for these indications. The ongoing Phase 2 trial is actively recruiting participants in Canada.
Hydroxychloroquine is being studied in a Phase 2 clinical trial with the identifier NCT04354649, titled "Immune-Mediated Pathophysiology And Clinical Triage Program." The trial is recruiting 46 participants with arthritis and arthralgia in Canada. It is a randomized, double-blind, placebo-controlled study.
Hydroxychloroquine is a small molecule drug being developed by Avalon GloboCare Corp. for arthritis and arthralgia. It is currently in Phase 2 clinical trials. No alternative names for this drug have been disclosed in the available information.